Genky DrugStores Co., Ltd. (TYO:9267)
Japan · Delayed Price · Currency is JPY 3,735.00
0.00 (0.00%)
Nov 13, 2026, 3:30 PM JST
Genky DrugStores Income Statement
Financials in millions JPY. Fiscal year is July - June.
Millions JPY. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 20, 2026 | Jun '26 Jun 20, 2026 | Jun '25 Jun 20, 2025 | Jun '24 Jun 20, 2024 | Jun '23 Jun 20, 2023 | Jun '22 Jun 20, 2022 |
| 224,099 | 220,638 | 200,786 | 184,860 | 169,059 | 154,639 | |
Revenue Growth | 8.38% | 9.89% | 8.62% | 9.35% | 9.32% | 8.61% |
Cost of Revenue | 178,419 | 175,715 | 159,896 | 147,239 | 134,505 | 123,685 |
Gross Profit | 45,680 | 44,923 | 40,890 | 37,621 | 34,554 | 30,954 |
Selling, General & Admin | 28,228 | 27,318 | 25,433 | 23,518 | 23,194 | 21,000 |
Operating Expenses | 34,848 | 33,938 | 31,231 | 28,605 | 27,844 | 25,279 |
Operating Income | 10,832 | 10,985 | 9,659 | 9,016 | 6,710 | 5,675 |
Interest Expense | -371 | -313 | -216 | -103 | -70 | -59 |
Interest & Investment Income | 18 | 16 | 10 | 7 | 8 | 9 |
Other Non Operating Income (Expenses) | 459 | 469 | 445 | 347 | 430 | 437 |
EBT Excluding Unusual Items | 10,938 | 11,157 | 9,898 | 9,267 | 7,078 | 6,062 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 25 |
Gain (Loss) on Sale of Assets | -6 | -9 | 5 | -14 | 10 | 1 |
Asset Writedown | - | - | -3 | -286 | -386 | -9 |
Other Unusual Items | 3 | 4 | 2 | -165 | 1 | 4 |
Pretax Income | 10,935 | 11,152 | 9,902 | 8,802 | 6,703 | 6,083 |
Income Tax Expense | 3,219 | 3,277 | 2,836 | 2,478 | 1,939 | 1,663 |
Net Income | 7,716 | 7,875 | 7,066 | 6,324 | 4,764 | 4,420 |
Net Income to Common | 7,716 | 7,875 | 7,066 | 6,324 | 4,764 | 4,420 |
Net Income Growth | 2.62% | 11.45% | 11.73% | 32.75% | 7.78% | -8.51% |
Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 30 |
Shares Outstanding (Diluted) | 31 | 31 | 30 | 30 | 30 | 30 |
Shares Change | 0.34% | 0.34% | 0.13% | 0.09% | -0.02% | 0.03% |
EPS (Basic) | 253.05 | 258.51 | 232.49 | 208.18 | 156.89 | 145.59 |
EPS (Diluted) | 252.39 | 257.70 | 232.04 | 207.94 | 156.79 | 145.44 |
EPS Growth | 2.27% | 11.06% | 11.59% | 32.62% | 7.81% | -8.54% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 20, 2026 | Jun '26 Jun 20, 2026 | Jun '25 Jun 20, 2025 | Jun '24 Jun 20, 2024 | Jun '23 Jun 20, 2023 | Jun '22 Jun 20, 2022 |
Free Cash Flow | - | -3,126 | -2,495 | 2,978 | -1,118 | -4,388 |
Free Cash Flow Per Share | - | -102.29 | -81.92 | 97.91 | -36.79 | -144.36 |
Dividend Per Share | 13.000 | 13.000 | 13.000 | 12.500 | 12.500 | 12.500 |
Dividend Growth | 0% | 0% | 4.00% | 0% | 0% | 0% |
Gross Margin | 20.38% | 20.36% | 20.36% | 20.35% | 20.44% | 20.02% |
Operating Margin | 4.83% | 4.98% | 4.81% | 4.88% | 3.97% | 3.67% |
Profit Margin | 3.44% | 3.57% | 3.52% | 3.42% | 2.82% | 2.86% |
Free Cash Flow Margin | - | -1.42% | -1.24% | 1.61% | -0.66% | -2.84% |
EBITDA | 18,175 | 18,118 | 15,951 | 14,582 | 11,665 | 10,267 |
EBITDA Margin | 8.11% | 8.21% | 7.94% | 7.89% | 6.90% | 6.64% |
D&A For EBITDA | 7,343 | 7,133 | 6,292 | 5,566 | 4,955 | 4,592 |
EBIT | 10,832 | 10,985 | 9,659 | 9,016 | 6,710 | 5,675 |
EBIT Margin | 4.83% | 4.98% | 4.81% | 4.88% | 3.97% | 3.67% |
Effective Tax Rate | 29.44% | 29.39% | 28.64% | 28.15% | 28.93% | 27.34% |